<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="d4555fb8-feec-4922-8c72-83819f2a1f6c"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="HUMAN PRESCRIPTION DRUG LABEL"/>
   <title>
      <content styleCode="bold">Cleocin<sup>®</sup> Vaginal Ovules</content>
      <br/>
      <content styleCode="bold">(clindamycin phosphate vaginal suppositories)</content>
   </title>
   <effectiveTime value="20250408"/>
   <setId root="3db26227-208d-4fdd-8426-1d9be5cda9b4"/>
   <versionNumber value="30"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="618054084" root="1.3.6.1.4.1.519.1"/>
            <name>Pharmacia &amp; Upjohn Company LLC</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="618054084" root="1.3.6.1.4.1.519.1"/>
                        <name>Pharmacia &amp; Upjohn Company LLC</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-7667" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-7667" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C82401" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="API MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-7667" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84731" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="PACK"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-7667" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C84732" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="LABEL"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="0009-7667" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="f07c988f-ca30-42c6-ba7a-47b60cad75e1"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL product data elements section"/>
               <effectiveTime value="20241231"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0009-7667" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Cleocin</name>
                        <formCode code="C42993" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="SUPPOSITORY"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>clindamycin phosphate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="100"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="EH6D7113I8" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CLINDAMYCIN PHOSPHATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="3U02EL437C" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>CLINDAMYCIN</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="3"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0009-7667-01" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="completed"/>
                                       <effectiveTime>
                                          <low value="19990813"/>
                                          <high value="20251231"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C102834" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 1: Convenience Kit of Co-Package" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="3"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code/>
                              <formCode code="C43168" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BLISTER PACK"/>
                              <asContent>
                                 <quantity>
                                    <numerator unit="1" value="1"/>
                                    <denominator value="1"/>
                                 </quantity>
                                 <containerPackagedProduct>
                                    <code code="0009-7667-05" codeSystem="2.16.840.1.113883.6.69"/>
                                    <formCode code="C43182" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="CARTON"/>
                                 </containerPackagedProduct>
                                 <subjectOf>
                                    <marketingAct>
                                       <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                       <statusCode code="active"/>
                                       <effectiveTime>
                                          <low value="20240203"/>
                                       </effectiveTime>
                                    </marketingAct>
                                 </subjectOf>
                              </asContent>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="NDA050767" root="2.16.840.1.113883.3.150"/>
                           <code code="C73594" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="NDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="19990813"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38313" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="VAGINAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="ID_e56f0670-732f-46b4-a8bf-7828247bb2a5">
               <id root="87fd0669-35f8-4e86-b2aa-e389ab729de6"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">FOR INTRAVAGINAL USE ONLY</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240206"/>
            </section>
         </component>
         <component>
            <section ID="ID_5ea9add4-5df8-48ba-b1a7-885730d30771">
               <id root="687438b6-159d-49bc-a8bb-ac9eb39fead8"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>DESCRIPTION</title>
               <text>
                  <paragraph>Clindamycin phosphate is a water-soluble ester of the semisynthetic antibiotic produced by a 7(S)-chloro-substitution of the 7(R)-hydroxyl group of the parent antibiotic lincomycin. The chemical name for clindamycin phosphate is methyl 7-chloro-6,7,8-trideoxy-6-(1-methyl-<content styleCode="italics">trans</content>-4-propyl-L-2-pyrrolidinecarboxamido)-1-thio-L-<content styleCode="italics">threo</content>-α-D-<content styleCode="italics">galacto</content>-octopyranoside 2-(dihydrogen phosphate). The monohydrate form has a molecular weight of 522.98, and the molecular formula is C<sub>18</sub>H<sub>34</sub>ClN<sub>2</sub>O<sub>8</sub>PS•H<sub>2</sub>O. The structural formula is represented below:</paragraph>
                  <renderMultiMedia ID="id280" referencedObject="MM1"/>
                  <paragraph>CLEOCIN Vaginal Ovules are semisolid, white to off-white suppositories for intravaginal administration. Each 2.5 g suppository contains clindamycin phosphate equivalent to 100 mg clindamycin in a base consisting of a mixture of glycerides of saturated fatty acids.</paragraph>
               </text>
               <effectiveTime value="20240206"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-ovules-01.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Clin_Pharm">
               <id root="3d687a55-603b-4fac-818c-103d77153ec2"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>CLINICAL PHARMACOLOGY</title>
               <text>
                  <paragraph>     </paragraph>
               </text>
               <effectiveTime value="20241011"/>
               <component>
                  <section ID="ID_dca0b0c5-3cb7-464e-a3bc-07705ac635b8">
                     <id root="1b9420e7-8153-457c-9978-57d434d2c1e4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Mechanism of Action</title>
                     <text>
                        <paragraph>Clindamycin is an antibacterial drug (See<linkHtml href="#micro"> MICROBIOLOGY</linkHtml>).</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_00ba12fc-0a24-4ed5-95fe-6e64f70bc51b">
                     <id root="f06a3772-22e0-42be-971c-c486de7e88f1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Pharmacokinetics</title>
                     <text>
                        <paragraph>Systemic absorption of clindamycin was estimated following a once-a-day intravaginal dose of one clindamycin phosphate vaginal suppository (equivalent to 100 mg clindamycin) administered to 11 healthy female volunteers for 3 days. Approximately 30% (range 6% to 70%) of the administered dose was absorbed systemically on day 3 of dosing based on area under the concentration-time curve (AUC). Systemic absorption was estimated using a subtherapeutic 100 mg intravenous dose of clindamycin phosphate as a comparator in the same volunteers. The mean AUC following day 3 of dosing with the suppository was 3.2 µg hr/mL (range 0.42 to 11 µg hr/mL). The C<sub>max</sub> observed on day 3 of dosing with the suppository averaged 0.27 µg/mL (range 0.03 to 0.67 µg/mL) and was observed about 5 hours after dosing (range 1 to 10 hours). In contrast, the AUC and C<sub>max</sub> after the single intravenous dose averaged 11 µg hr/mL (range 5.1 to 26 µg hr/mL) and 3.7 µg/mL (range 2.4 to 5.0 µg/mL), respectively. The mean apparent elimination half-life after dosing with the suppository was 11 hours (range 4 to 35 hours) and is considered to be limited by the absorption rate.</paragraph>
                        <paragraph>The results from this study showed that systemic exposure to clindamycin (based on AUC) from the suppository was, on average, three-fold lower than that from a single subtherapeutic 100 mg intravenous dose of clindamycin. In addition, the recommended daily and total doses of intravaginal clindamycin suppository are far lower than those typically administered in oral or parenteral clindamycin therapy (100 mg of clindamycin per day for 3 days equivalent to about 30 mg absorbed per day from the ovule relative to 600 to 2700 mg/day for up to 10 days or more, orally or parenterally). The overall systemic exposure to clindamycin from Cleocin Vaginal Ovules is substantially lower than the systemic exposure from therapeutic doses of oral clindamycin hydrochloride (two-fold to 20-fold lower) or parenteral clindamycin phosphate (40-fold to 50-fold lower).</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="micro">
               <id root="b519f854-c270-48d6-9114-b2d631e6fef4"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <title>MICROBIOLOGY</title>
               <effectiveTime value="20240206"/>
               <component>
                  <section ID="ID_4365db4f-390a-4997-967e-a9cbb3a81ab2">
                     <id root="b770ca6c-46ef-4bba-acf2-fe978a229c53"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Mechanism of Action</title>
                     <text>
                        <paragraph>Clindamycin inhibits bacterial protein synthesis by binding to the 23S RNA of the 50S subunit of the ribosome. Clindamycin is predominantly bacteriostatic.</paragraph>
                        <paragraph>Although clindamycin phosphate is inactive <content styleCode="italics">in vitro,</content> rapid <content styleCode="italics">in vivo</content> hydrolysis converts it to active clindamycin.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_3d7576b5-e712-48f7-8418-9491ca720382">
                     <id root="d57b907b-4815-4691-aab1-61fb421857a6"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Resistance</title>
                     <text>
                        <paragraph>Resistance to clindamycin is most often caused by modification of the target site on the ribosome, usually by chemical modification of RNA bases or by point mutations in RNA or occasionally in proteins. Cross resistance has been demonstrated between lincosamides, macrolides and streptogramins B in some organisms. Cross resistance has been demonstrated between clindamycin and lincomycin.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5dd872bb-2240-49e0-b389-7d6e3818416a">
                     <id root="dca770a6-d6db-48a0-9808-424494ae02e7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Antibacterial Activity</title>
                     <text>
                        <paragraph>Culture and sensitivity testing of bacteria are not routinely performed to establish the diagnosis of bacterial vaginosis (see <linkHtml href="#Indications_and_Usage">INDICATIONS AND USAGE</linkHtml>); standard methodology for the susceptibility testing of the potential bacterial pathogens, <content styleCode="italics">Gardnerella vaginalis, Mobiluncus</content> spp., or <content styleCode="italics">Mycoplasma hominis</content>, has not been defined.</paragraph>
                        <paragraph>The following <content styleCode="italics">in vitro</content> data are available but their clinical significance is unknown. Clindamycin is active in vitro against most isolates of the following organisms reported to be associated with bacterial vaginosis:</paragraph>
                        <list listType="unordered">
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Bacteroides</content> spp.</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Gardnerella vaginalis</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Mobiluncus</content> spp.</item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Mycoplasma hominis</content>
                           </item>
                           <item>
                              <caption>•</caption>
                              <content styleCode="italics">Peptostreptococcus</content> spp.</item>
                        </list>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Indications_and_Usage">
               <id root="0daaea8f-ee17-49ec-ab15-412cea1378db"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>CLEOCIN Vaginal Ovules are indicated for 3-day treatment of bacterial vaginosis in non-pregnant women. There are no adequate and well-controlled studies of CLEOCIN Vaginal Ovules in pregnant women.</paragraph>
                  <paragraph>
                     <content styleCode="bold">NOTE: </content>For purposes of this indication, a clinical diagnosis of bacterial vaginosis is usually defined by the presence of a homogeneous vaginal discharge that (a) has a pH of greater than 4.5, (b) emits a "fishy" amine odor when mixed with a 10% KOH solution, and (c) contains clue cells on microscopic examination. Gram's stain results consistent with a diagnosis of bacterial vaginosis include (a) markedly reduced or absent <content styleCode="italics">Lactobacillus</content> morphology, (b) predominance of <content styleCode="italics">Gardnerella</content> morphotype, and (c) absent or few white blood cells.</paragraph>
                  <paragraph>Other pathogens commonly associated with vulvovaginitis, e.g., <content styleCode="italics">Trichomonas vaginalis</content>, <content styleCode="italics">Chlamydia trachomatis</content>, <content styleCode="italics">Neisseria gonorrhoeae</content>, <content styleCode="italics">Candida albicans</content>, and herpes simplex virus, should be ruled out.</paragraph>
               </text>
               <effectiveTime value="20240206"/>
            </section>
         </component>
         <component>
            <section ID="ID_59b567ec-a148-47af-baa1-c13cac531732">
               <id root="ffd3b0a2-9dee-44e2-90b8-6d5d5386b63d"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>CONTRAINDICATIONS</title>
               <text>
                  <paragraph>CLEOCIN Vaginal Ovules are contraindicated in individuals with a history of hypersensitivity to clindamycin, lincomycin, or any of the components of this vaginal suppository. CLEOCIN Vaginal Ovules are also contraindicated in individuals with a history of regional enteritis, ulcerative colitis, or a history of "antibiotic-associated" colitis.</paragraph>
               </text>
               <effectiveTime value="20240206"/>
            </section>
         </component>
         <component>
            <section ID="Warnings">
               <id root="c8be69b8-fab5-43dd-b5a2-869a77fc058e"/>
               <code code="34071-1" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS SECTION"/>
               <title>WARNINGS</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">Pseudomembranous colitis has been reported with nearly all antibacterial agents, including clindamycin, and may range in severity from mild to life-threatening. Orally and parenterally administered clindamycin has been associated with severe colitis, which may end fatally. Diarrhea, bloody diarrhea, and colitis (including pseudomembranous colitis) have been reported with the use of orally and parenterally administered clindamycin, as well as with topical (dermal and vaginal) formulations of clindamycin. Therefore, it is important to consider this diagnosis in patients who present with diarrhea subsequent to the administration of CLEOCIN Vaginal Ovules, because approximately 30% of the clindamycin dose is systemically absorbed from the vagina.</content>
                  </paragraph>
                  <paragraph>Treatment with antibacterial agents alters the normal flora of the colon and may permit overgrowth of clostridia. Studies indicate that a toxin produced by <content styleCode="italics">Clostridioides difficile</content> is a primary cause of "antibiotic-associated" colitis.</paragraph>
                  <paragraph>After the diagnosis of pseudomembranous colitis has been established, therapeutic measures should be initiated. Mild cases of pseudomembranous colitis usually respond to discontinuation of the drug alone. In moderate to severe cases, consideration should be given to management with fluids and electrolytes, protein supplementation, and treatment with an antibacterial drug clinically effective against <content styleCode="italics">Clostridioides difficile</content> colitis.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Onset of pseudomembranous colitis symptoms may occur during or after antimicrobial treatment.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20240206"/>
            </section>
         </component>
         <component>
            <section ID="ID_a3e0d47f-3a6f-4016-a503-9968cfcf1154">
               <id root="b4191125-07d1-44fe-9a90-5d6a59b40ab6"/>
               <code code="42232-9" codeSystem="2.16.840.1.113883.6.1" displayName="PRECAUTIONS SECTION"/>
               <title>PRECAUTIONS</title>
               <effectiveTime value="20240206"/>
               <component>
                  <section ID="ID_9745b112-3157-4d0d-9f9a-e587d4a1378a">
                     <id root="1b5ea84c-6171-4f18-a6c6-5c56f0e9af86"/>
                     <code code="34072-9" codeSystem="2.16.840.1.113883.6.1" displayName="GENERAL PRECAUTIONS SECTION"/>
                     <title>General</title>
                     <text>
                        <paragraph>The use of CLEOCIN Vaginal Ovules may result in the overgrowth of nonsusceptible organisms in the vagina. In clinical studies using CLEOCIN Vaginal Ovules, treatment-related moniliasis was reported in 2.7% and vaginitis in 3.6% of 589 nonpregnant women. Moniliasis, as reported here, includes the terms: vaginal or nonvaginal moniliasis and fungal infection. Vaginitis includes the terms: vulvovaginal disorder, vaginal discharge, and vaginitis/vaginal infection.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_27e2d445-c07c-4c41-ada3-a9ecc9e9343d">
                     <id root="8eda04f1-e009-4d43-8523-e872eb639a0a"/>
                     <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
                     <title>Information for the Patient</title>
                     <text>
                        <paragraph>The patient should be instructed not to engage in vaginal intercourse or use other vaginal products (such as tampons or douches) during treatment with this product.</paragraph>
                        <paragraph>
                           <content styleCode="bold">The patient should also be advised that these suppositories use an oleaginous base that may weaken latex or rubber products such as condoms or vaginal contraceptive diaphragms. Therefore, the use of such products within 72 hours following treatment with CLEOCIN Vaginal Ovules is not recommended.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_642602ce-18e0-4669-bb35-1df9141127fa">
                     <id root="ae086394-848a-4862-a389-87bc5ed1ae35"/>
                     <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
                     <title>Drug Interactions</title>
                     <text>
                        <paragraph>Systemic clindamycin has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Therefore, it should be used with caution in patients receiving such agents.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_5365bdac-00d9-415c-8523-fe50939199d6">
                     <id root="8ead31a1-b3d4-456c-924b-8de269be861b"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>Long-term studies in animals have not been performed with clindamycin to evaluate carcinogenic potential. Genotoxicity tests performed included a rat micronucleus test and an Ames test. Both tests were negative. Fertility studies in rats treated orally with up to 300 mg/kg/day (31 times the human exposure based on mg/m<sup>2</sup>) revealed no effects on fertility or mating ability.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_45fc40f6-0d0e-4aec-9e4c-1f4e0315757d">
                     <id root="72ca6c47-f281-43e0-abef-8b7571f02d36"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>Pregnancy</title>
                     <effectiveTime value="20240206"/>
                     <component>
                        <section ID="ID_e43ba1cb-0904-47d0-9e95-057b62ac66da">
                           <id root="76707927-5e5e-4d0d-9285-86b566266213"/>
                           <code code="34077-8" codeSystem="2.16.840.1.113883.6.1" displayName="TERATOGENIC EFFECTS SECTION"/>
                           <title>
                              <content styleCode="bold">Teratogenic effects</content>
                           </title>
                           <text>
                              <paragraph>In clinical trials with pregnant women, the systemic administration of clindamycin during the second and third trimesters, has not been associated with an increased frequency of congenital abnormalities.</paragraph>
                              <paragraph>Clindamycin vaginal ovules should be used during the first trimester of pregnancy only if clearly needed and the benefits outweigh the risks. There are no adequate and well-controlled studies of CLEOCIN Vaginal Ovules in pregnant women during the first trimester of pregnancy.</paragraph>
                              <paragraph>CLEOCIN Vaginal Cream, 2%, has been studied in pregnant women during the second trimester. In women treated for 7 days, abnormal labor was reported more frequently in patients who received CLEOCIN Vaginal Cream compared to those receiving placebo (1.1% vs. 0.5% of patients, respectively).</paragraph>
                              <paragraph>Reproduction studies have been performed in rats and mice using oral and parenteral doses of clindamycin up to 600 mg/kg/day (62 and 25 times, respectively, the maximum human dose based on body surface area) and have revealed no evidence of harm to the fetus due to clindamycin. Cleft palates were observed in fetuses from one mouse strain treated intraperitoneally with clindamycin at 200 mg/kg/day (about 10 times the recommended dose based on body surface area conversions). Since this effect was not observed in other mouse strains or in other species, the effect may be strain specific.</paragraph>
                           </text>
                           <effectiveTime value="20240206"/>
                        </section>
                     </component>
                  </section>
               </component>
               <component>
                  <section ID="ID_7a7f254f-e211-45df-97ec-894e26c587aa">
                     <id root="64283b24-c4cb-4fb9-85fa-378c054b2b55"/>
                     <code code="34080-2" codeSystem="2.16.840.1.113883.6.1" displayName="NURSING MOTHERS SECTION"/>
                     <title>Nursing Mothers</title>
                     <text>
                        <paragraph>Limited published data based on breast milk sampling reports that clindamycin appears in human breast milk in the range of less than 0.5 to 3.8 mcg/mL at dosages of 150 mg orally to 600 mg intravenously. It is not known if clindamycin is excreted in human breast milk following the use of vaginally administered clindamycin phosphate.</paragraph>
                        <paragraph>Clindamycin has the potential to cause adverse effects on the breast-fed infant's gastrointestinal flora. If clindamycin is required by a nursing mother, it is not a reason to discontinue breastfeeding, but an alternate drug may be preferred. Monitor the breast-fed infant for possible adverse effects on the gastrointestinal flora, such as diarrhea, candidiasis (thrush, diaper rash) or rarely, blood in the stool indicating possible antibiotic-associated colitis.</paragraph>
                        <paragraph>The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for clindamycin and any potential adverse effects on the breast-fed child from clindamycin or from the underlying maternal condition.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_a3aadf94-6355-4dd3-ad1f-bf3b1f1e9628">
                     <id root="afca0193-735d-475d-b473-240919a21603"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>Pediatric Use</title>
                     <text>
                        <paragraph>The safety and efficacy of CLEOCIN Vaginal Ovules in the treatment of bacterial vaginosis in post-menarchal females have been established on the extrapolation of clinical trial data from adult women. When a post-menarchal adolescent presents to a health professional with bacterial vaginosis symptoms, a careful evaluation for sexually transmitted diseases and other risk factors for bacterial vaginosis should be considered. The safety and efficacy of CLEOCIN Vaginal Ovules in pre-menarchal females have not been established.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_f058523b-180d-4405-9b9f-1ec7e2374aac">
                     <id root="986f796b-f0b3-49e4-9e42-cabf874e3771"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>Geriatric Use</title>
                     <text>
                        <paragraph>Clinical studies of CLEOCIN Vaginal Ovules did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Adverse_Reactions">
               <id root="2598841a-b7fd-46ea-8890-5220f0dc3698"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>ADVERSE REACTIONS</title>
               <effectiveTime value="20240206"/>
               <component>
                  <section ID="ID_50ac1484-f321-4a05-8df3-534a73d87cdf">
                     <id root="b453fbf8-aa31-43e8-8815-3a69bb96292c"/>
                     <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
                     <title>Clinical Trials</title>
                     <text>
                        <paragraph>In clinical trials, 3 (0.5%) of 589 nonpregnant women who received treatment with CLEOCIN Vaginal Ovules discontinued therapy due to drug-related adverse events. Adverse events judged to have a reasonable possibility of having been caused by clindamycin phosphate vaginal suppositories were reported for 10.5% of patients. Events reported by 1% or more of patients receiving CLEOCIN Vaginal Ovules were as follows:</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Urogenital system: </content>
                           </content>Vulvovaginal disorder (3.4%), vaginal pain (1.9%), and vaginal moniliasis (1.5%).</paragraph>
                        <paragraph>
                           <content styleCode="bold">
                              <content styleCode="italics">Body as a whole: </content>
                           </content>Fungal infection (1.0%).</paragraph>
                        <paragraph>Other events reported by &lt;1% of patients included:</paragraph>
                        <paragraph>
                           <content styleCode="italics">Urogenital system: </content>Menstrual disorder, dysuria, pyelonephritis, vaginal discharge, and vaginitis/vaginal infection.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Body as a whole: </content>Abdominal cramps, localized abdominal pain, fever, flank pain, generalized pain, headache, localized edema, and moniliasis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Digestive system: </content>Diarrhea, nausea, and vomiting.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Skin: </content>Nonapplication-site pruritis, rash, application-site pain, and application-site pruritis.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
               <component>
                  <section ID="ID_43ba0aae-f7b3-465c-8d20-8a8d92d8687b">
                     <id root="34e7c99e-8a39-49f3-86e9-65d2a79105ea"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>Other clindamycin formulations</title>
                     <text>
                        <paragraph>The overall systemic exposure to clindamycin from CLEOCIN Vaginal Ovules is substantially lower than the systemic exposure from therapeutic doses of oral clindamycin hydrochloride (two-fold to 20-fold lower) or parenteral clindamycin phosphate (40-fold to 50-fold lower). (See <linkHtml href="#Clin_Pharm">CLINICAL PHARMACOLOGY</linkHtml>.) Although these lower levels of exposure are less likely to produce the common reactions seen with oral or parenteral clindamycin, the possibility of these and other  reactions cannot be excluded.</paragraph>
                        <paragraph>The following adverse reactions and altered laboratory tests have been reported with the <content styleCode="bold">oral or parenteral</content> use of clindamycin and may also occur following administration of CLEOCIN Vaginal Ovules:</paragraph>
                        <paragraph>Infections and Infestations: <content styleCode="italics">Clostridioides difficile</content> colitis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal: </content>Abdominal pain, esophagitis, nausea, vomiting, diarrhea, and pseudomembranous colitis. (See <linkHtml href="#Warnings">WARNINGS</linkHtml>.)</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hematopoietic: </content>Transient neutropenia (leukopenia), eosinophilia, agranulocytosis, and thrombocytopenia have been reported. No direct etiologic relationship to concurrent clindamycin therapy could be made in any of these reports.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hypersensitivity Reactions: </content>Maculopapular rash and urticaria have been observed during drug therapy. Generalized mild to moderate morbilliform-like skin rashes are the most frequently reported of all adverse reactions. Cases of Acute Generalized Exanthematous Pustulosis (AGEP), erythema multiforme, some resembling Stevens-Johnson syndrome, have been associated with clindamycin. A few cases of anaphylactoid reactions have been reported. If a hypersensitivity reaction occurs, the drug should be discontinued.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Liver: </content>Jaundice and abnormalities in liver function tests have been observed during clindamycin therapy.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Musculoskeletal:</content> Cases of polyarthritis have been reported.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Renal: </content>Acute kidney injury</paragraph>
                        <paragraph>
                           <content styleCode="italics">Immune System:</content> Drug reaction with eosinophilia and systemic symptoms (DRESS) cases have been reported.</paragraph>
                        <paragraph>There have been reports of pseudomembranous colitis following the administration of clindamycin vaginal cream.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_27ec8ed1-9674-45c7-8e80-df98c6471444">
               <id root="c0d497ba-1f3f-49f5-9631-381dc5648176"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>OVERDOSAGE</title>
               <text>
                  <paragraph>Vaginally applied clindamycin phosphate contained in CLEOCIN Vaginal Ovules could be absorbed in sufficient amounts to produce systemic effects. (See <linkHtml href="#Warnings">WARNINGS</linkHtml> and <linkHtml href="#Adverse_Reactions">ADVERSE REACTIONS</linkHtml>.)</paragraph>
               </text>
               <effectiveTime value="20240206"/>
            </section>
         </component>
         <component>
            <section ID="ID_981dc891-197f-4c8c-9f4e-f9ee4ede96ac">
               <id root="362fd580-0e60-46e0-a278-6ba82113176d"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>DOSAGE AND ADMINISTRATION</title>
               <text>
                  <paragraph>The recommended dose is one CLEOCIN Vaginal Ovule (containing clindamycin phosphate equivalent to 100 mg clindamycin per 2.5 g suppository) intravaginally per day, preferably at bedtime, for 3 consecutive days.</paragraph>
               </text>
               <effectiveTime value="20240206"/>
            </section>
         </component>
         <component>
            <section ID="ID_eb630ddd-6fa9-4db1-b5da-0aacd0ac1f7c">
               <id root="67ac7902-10da-4c70-8f43-c98b99e9fa5d"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>HOW SUPPLIED</title>
               <text>
                  <paragraph>CLEOCIN Vaginal Ovules are supplied as follows:</paragraph>
                  <table styleCode="Noautorules" width="75%">
                     <col width="45%"/>
                     <col width="29%"/>
                     <tbody>
                        <tr>
                           <td valign="middle">
                              <paragraph>Carton of three suppositories with one applicator</paragraph>
                           </td>
                           <td align="right" valign="middle">
                              <paragraph>NDC 0009-7667-01</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td valign="middle">
                              <paragraph>Carton of three suppositories without the applicator</paragraph>
                           </td>
                           <td align="right" valign="middle">
                              <paragraph>NDC 0009-7667-05</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241011"/>
               <component>
                  <section ID="ID_ba430a50-cf1b-43d9-9c0e-e95b5f21369a">
                     <id root="57bcc756-3042-4afa-873a-ea6cd6461da8"/>
                     <code code="44425-7" codeSystem="2.16.840.1.113883.6.1" displayName="STORAGE AND HANDLING SECTION"/>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Important Information: </content>Store at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F) [see USP Controlled Room Temperature].</paragraph>
                        <paragraph>
                           <content styleCode="bold">Caution: </content>Avoid heat over 30°C (86°F). Avoid high humidity. See end of carton for the lot number and expiration date.</paragraph>
                     </text>
                     <effectiveTime value="20240206"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_354898fe-bb31-43b4-bf54-aa947a7d771c">
               <id root="06f0ee4d-95b7-45ce-8030-d5f2037134b3"/>
               <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
               <text>
                  <paragraph>
                     <content styleCode="bold">Rx only</content>
                  </paragraph>
                  <paragraph>This product's labeling may have been updated. For the most recent prescribing information, please visit <linkHtml href="https://www.pfizer.com/">www.pfizer.com</linkHtml>.</paragraph>
                  <renderMultiMedia ID="id623" referencedObject="MM2"/>
                  <paragraph>LAB-0047-16.0<br/>Revised 03/2025</paragraph>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-ovules-02.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7e33f6ed-061b-4d7a-8c11-2f31306f60e1">
               <id root="2120fc83-8772-4258-9853-dbe0aa87c0a3"/>
               <code code="42230-3" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PATIENT PACKAGE INSERT SECTION"/>
               <title>Cleocin<sup>®</sup> Vaginal Ovules<br/>(clindamycin phosphate vaginal suppositories)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">DIRECTIONS FOR USE</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">How do I use CLEOCIN Vaginal Ovules?</content>
                  </paragraph>
                  <paragraph>For vaginal use only. Do not take by mouth.</paragraph>
                  <paragraph>Use one CLEOCIN Vaginal Ovule daily, preferably at bedtime, for 3 days in a row.</paragraph>
                  <paragraph>Do not use this product if the foiled pouches containing vaginal ovules are torn, opened, or incompletely sealed.</paragraph>
                  <paragraph>Read the full directions below before using.</paragraph>
                  <paragraph>
                     <content styleCode="bold">Insertion with the applicator:</content>
                  </paragraph>
                  <list listType="ordered">
                     <item>
                        <caption>1.</caption>
                        <content ID="bkmrkfigure1">Remove the vaginal ovule from its packaging (See Figure 1).</content>
                     </item>
                  </list>
                  <renderMultiMedia ID="fig1" referencedObject="MM3"/>
                  <list listType="ordered">
                     <item>
                        <caption>2.</caption>Pull back the plunger about an inch and place the vaginal ovule in the wider end of the applicator barrel (See Figure 2).</item>
                  </list>
                  <renderMultiMedia ID="id659" referencedObject="MM4"/>
                  <list listType="ordered">
                     <item>
                        <caption>3.</caption>Hold the applicator as shown and gently insert the end of the applicator into the vagina as far as it will go comfortably. This can be done while lying on your back with your knees bent (as shown in Figure 3), or while standing with your feet apart and your knees bent.</item>
                  </list>
                  <renderMultiMedia ID="id663" referencedObject="MM5"/>
                  <list listType="ordered">
                     <item>
                        <caption>4.</caption>While holding the barrel of the applicator in place, push the plunger in until it stops to release the vaginal ovule. Remove the applicator from the vagina.</item>
                     <item>
                        <caption>5.</caption>Clean the applicator after each use. Pull the two pieces apart and wash them with soap and warm water. Rinse well and dry. Put the two pieces back together and store in a clean, dry place.</item>
                     <item>
                        <caption>6.</caption>Once inside the vagina, the ovule melts. Lie down as soon as possible. This will keep leakage to a minimum.</item>
                     <item>
                        <caption>7.</caption>Repeat steps 1 through 6, before bedtime, for the next 2 days.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">Insertion without the applicator:</content>
                  </paragraph>
                  <list listType="ordered">
                     <item>
                        <caption>1.</caption>Remove the vaginal ovule from its packaging (See <linkHtml href="#bkmrkfigure1">Figure 1</linkHtml> above).</item>
                     <item>
                        <caption>2.</caption>Holding the ovule with your thumb and a finger, insert it into the vagina (See Figure 4).</item>
                     <item>
                        <caption> </caption>
                        <renderMultiMedia ID="id681" referencedObject="MM6"/>
                        <paragraph>                     <content styleCode="bold">Figure 4</content>
                        </paragraph>
                     </item>
                     <item>
                        <caption>3.</caption>Using your finger, gently push the ovule into the vagina as far as it will comfortably go (See Figure 5).</item>
                     <item>
                        <caption> </caption>
                        <renderMultiMedia ID="id685" referencedObject="MM7"/>
                        <paragraph>                     <content styleCode="bold">Figure 5</content>
                        </paragraph>
                     </item>
                     <item>
                        <caption>4.</caption>Once inside the vagina, the ovule melts. Lie down as soon as possible. This will keep leakage to a minimum.</item>
                     <item>
                        <caption>5.</caption>Repeat steps 1 through 4, before bedtime, for the next 2 days.</item>
                  </list>
                  <paragraph>
                     <content styleCode="bold">STORAGE CONDITIONS:</content>
                  </paragraph>
                  <paragraph>Store at 25°C (77°F); excursions permitted to 15 – 30°C (59 – 86°F) [see USP Controlled Room Temperature].</paragraph>
                  <paragraph>
                     <content styleCode="bold">Caution: </content>Avoid heat over 30°C (86°F). Avoid high humidity. See end of carton for the lot number and expiration date.</paragraph>
                  <renderMultiMedia ID="id695" referencedObject="MM8"/>
                  <paragraph>LAB-0649-3.0<br/>Revised March 2025</paragraph>
               </text>
               <effectiveTime value="20250408"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>Figure 1</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-ovules-03.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM4">
                     <text>Figure 2</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-ovules-04.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>Figure 3</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-ovules-05.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>Figure 4</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-ovules-06.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>Figure 5</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-ovules-07.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM8">
                     <text>Logo</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-ovules-08.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_b4360a9f-de09-4400-ba00-2ad53e18a970">
               <id root="961c95c6-a549-4be8-b760-ceb694229ef5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg Suppository Blister Pack</title>
               <text>
                  <paragraph>Cleocin<sup>®</sup>
                     <br/>100 mg<br/>(clindamycin phosphate<br/>vaginal suppositories)<br/>Dist. by Pharmacia &amp; Upjohn Co. LLC <br/>A subsidiary of Pfizer Inc., NY, NY 10017</paragraph>
                  <paragraph>Lot<br/>Exp</paragraph>
                  <renderMultiMedia ID="id746" referencedObject="MM9"/>
               </text>
               <effectiveTime value="20240206"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>PRINCIPAL DISPLAY PANEL - 100 mg Suppository Blister Pack</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-ovules-09.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_7821afca-ca70-4e69-bddd-002c4e814276">
               <id root="83da9857-1ddd-4da3-bb37-b49aa0f36e04"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg Suppository Blister Pack Carton</title>
               <text>
                  <paragraph>NDC 0009-7667-01</paragraph>
                  <paragraph>Pfizer</paragraph>
                  <paragraph>Cleocin<sup>®</sup>
                     <br/>Vaginal Ovules<br/>(clindamycin phosphate<br/>vaginal suppositories)</paragraph>
                  <paragraph>equivalent to<br/>100 mg*<br/>clindamycin</paragraph>
                  <paragraph>For Intravaginal Use Only</paragraph>
                  <paragraph>3 Suppositories with one applicator</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia ID="id773" referencedObject="MM10"/>
               </text>
               <effectiveTime value="20240206"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>PRINCIPAL DISPLAY PANEL - 100 mg Suppository Blister Pack Carton</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-ovules-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="ID_2b36fea3-4419-49b5-931f-02fe56bfbb5c">
               <id root="47793d10-5c84-4c95-a3b7-71782723249b"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PRINCIPAL DISPLAY PANEL - 100 mg Suppository Blister Pack Carton - NDC 0009-7667-05</title>
               <text>
                  <paragraph>NDC 0009-7667-05</paragraph>
                  <paragraph>Pfizer</paragraph>
                  <paragraph>Cleocin<sup>®</sup>
                     <br/>Vaginal Ovules<br/>(clindamycin phosphate<br/>vaginal suppositories)</paragraph>
                  <paragraph>equivalent to<br/>100 mg*<br/>clindamycin</paragraph>
                  <paragraph>For Intravaginal Use Only</paragraph>
                  <paragraph>3 Suppositories</paragraph>
                  <paragraph>Rx only</paragraph>
                  <renderMultiMedia ID="id800" referencedObject="MM11"/>
               </text>
               <effectiveTime value="20240206"/>
               <component>
                  <observationMedia ID="MM11">
                     <text>PRINCIPAL DISPLAY PANEL - 100 mg Suppository Blister Pack Carton - NDC 0009-7667-05</text>
                     <value mediaType="image/jpeg" xsi:type="ED">
                        <reference value="cleocin-ovules-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>